document.write("
"); document.write("
Käsmann,\ L.*\ ; Taugner,\ J.*\ ; Eze,\ C.*\ ; Nieto,\ A.*\ ; Pelikan,\ C.\ ; Floersch,\ B.*\ ; Kenndoff,\ S.*\ ; Hofer,\ T.P.\ ; Nößner,\ E.\ ; Schulz,\ C.*\ ; Unterrainer,\ M.*\ ; Tufman,\ A.*\ ; Klauschen,\ F.*\ ; Jung,\ A.*\ ; Neumann,\ J.*\ ; Kumbrink,\ J.*\ ; Reinmuth,\ N.*\ ; Bartenstein,\ P.*\ ; Belka,\ C.*\ ; Manapov,\ F.*
"); document.write("
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): Protocol for a prospective longitudinal biomarker study.
"); document.write("
Transl. Lung Cancer Res. 11, 1503-1509 (2022)
"); document.write("
");